Accessibility Menu
Maia Biotechnology logo

Maia Biotechnology(NYSEMKT) MAIA

Market Cap$80.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-70%
5 YearN/A
1 Year-13%
1 Month+11%
$1.32
-1.13%
-0.02Today
After hours$1.30-$0.02 (-1.14%)
Maia Biotechnology last closing stock price
MetricPriceDate
Last closeUSD 1.332026-08-28
Maia Biotechnology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.32%USD 1.392026-08-21
1 month+10.83%USD 1.202026-07-29
3 month-4.32%USD 1.392026-05-29
Year to date-13.07%USD 1.532025-12-31
1 year-12.5%USD 1.522025-08-28
3 year-27.72%USD 1.842023-08-29
Since inception-70.18%USD 4.462022-07-28

Maia Biotechnology Financials at a Glance

Market Cap

$80.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.85M

EPS (TTM)

-$0.63

P/E Ratio

-2.10

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.32

Volume

258,682

Open

$1.33

Previous Close

$1.31

Daily Range

$1.30 - $1.33

52-Week Range

$0.87 - $3.19

Estimated Earnings Date

Nov 6, 2026

MAIA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Maia Biotechnology

MAIA develops new cancer treatments for patients with limited options. Its main drug aims to help those with advanced lung cancer. The company focuses on therapies that may work when other treatments fail.

Lab Bench to Bedside: MAIA’s Main Offerings

  • Ateganosine (THIO): Investigational drug for advanced lung cancer; targets cancer cell DNA and boosts immune response. 0% of revenue (pre-commercial).
  • THIO-101 Trial: Phase 2 study for non-small cell lung cancer, including patients resistant to standard therapies. 0% of revenue.
  • THIO-104 Trial: Phase 3 trial comparing THIO to chemotherapy in late-stage lung cancer. 0% of revenue.
  • Pipeline Programs: Early research on new drugs for liver, colon, and small cell lung cancers. 0% of revenue.
  • Strategic Collaborations: Partnerships with Regeneron, BeOne Medicines, and Roche for clinical trial drug supply. 0% of revenue.

Growth and Expansion: MAIA’s Moves on the Board

  • Launched Phase 3 THIO-104 trial in lung cancer in 2025.
  • Expanded THIO-101 trial to more patient groups in 2025.
  • Signed new supply deals with BeOne Medicines and Roche in 2025.
  • Entered global clinical trial sites in Europe, Asia, Australia, and the U.S. since 2024.
  • Advanced seven new drug candidates into preclinical testing by 2025.

What Makes MAIA Stand Out in the Crowd

MAIA’s lead drug uses a dual approach: it attacks cancer cell DNA and helps the immune system recognize tumors. The company holds patents covering its main drug and its use with other cancer therapies. MAIA relies on partnerships for drug supply and global clinical trial reach.

Five Things You Need to Know

  • No revenue in 2025, 2024, or 2023; company is pre-commercial.
  • Net loss was $22.4 million in 2025, a 4% improvement from 2024.
  • Research and development expenses rose 45% to $14.5 million in 2025.
  • Cash was $8.7 million at December 31, 2025, down from $9.6 million in 2024.
  • Raised $17.9 million in 2025 through private placements and offerings.

Bottom Line

MAIA is a small biotech focused on new cancer drugs, with no sales yet. Its future depends on clinical trial success and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Vlad Vitoc, MD, MBA

Website

maiabiotech.com

Headquarters

Chicago, IL 60606, US

MAIA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-211.15%

Return on Capital

-1021.51%

Return on Assets

-95.06%

Earnings Yield

-47.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$80.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.83M

Volume

258.68K

Avg. Volume

663.07K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$28.95M

EBITDA

-$17.11M

Operating Cash Flow

-$22.57M

Capital Expenditure

$0.00

Free Cash Flow

-$22.57M

Cash & ST Invst.

$27.60M

Total Debt

$0.00

Maia Biotechnology Performance Analysis

Maia Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Maia Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Maia Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.7548.7%
20232023-12-31USD -1.49-14.7%
20242024-12-31USD -1.05-29.7%
20252025-12-31USD -0.70-33.4%
Maia Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-50.0%
Q42025-12-3165.2%
Q12026-03-31-48.9%
Q22026-06-307.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$80.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.22M

N/A

Employees

13

N/A

Net Income

-$7.94M

-48.6%

EBITDA

-$7.57M

-41.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$27.60M

+172.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-95.06%

N/A

Return on Invested Capital

-1.32%

N/A

Free Cash Flow

-$6.75M

-63.2%

Operating Cash Flow

-$6.75M

-63.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RNXTRenovoRx, Inc.
$1.93+15.57%
ANVSAnnovis Bio, Inc.
$1.72+0.00%
PYPDPolyPid Ltd.
$5.14+1.38%
CELUCelularity Inc.
$1.85+17.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About MAIA

What is the current price of Maia Biotechnology?

Maia Biotechnology is trading at $1.31 per share.

What is the 52-week range for Maia Biotechnology?

Over the past 52 weeks, Maia Biotechnology has traded between $0.87 and $3.19.

How much debt does Maia Biotechnology have?

As of the most recent reporting period, Maia Biotechnology reported total debt of $0.00.

How much cash does Maia Biotechnology have on hand?

Maia Biotechnology reported $27.60M in cash and cash equivalents in its most recent financial results.

What is Maia Biotechnology’s dividend yield?

Maia Biotechnology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services